Nanoparticles developed at New York City-based Weill Cornell Medicine and Cornell Engineering can improve the effectiveness of immunotherapy, according to a study published Dec. 29 in Nature Nanotechnology.
The particles, known as Cornell prime dots or C’dots, are ultrasmall fluorescent core-shell silica nanoparticles. The nanoparticles can “reprogram the tumor microenvironment,” enabling a better response to treatment, researchers said in a Jan. 5 news release from the Ithaca, N.Y.-based university.
The C’dots are “not simply acting as a passive carrier or delivery vehicle; these nanoparticles are intrinsically active therapeutic agents,” Michelle Bradbury, MD, PhD, lead study author and the endowed professor of imaging research in radiology at Weill Cornell Medicine, said in the release.
Read the full study here.
Leave a Reply